

Bay 65-1942 (free base)

Catalog No: tcsc0624



Available Sizes

Size: 5mg

Size: 10mg



Specifications

CAS No:

600734-02-9

Formula:

$C_{22}H_{25}N_3O_4$

Pathway:

NF-κB

Target:

IKK

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

395.45

Product Description


Bay 65-1942 free base is an ATP-competitive and selective **IKKβ** inhibitor.

IC50 & Target: IKKβ^[1]

In Vitro: Delivery of Bay 65-1942 prior to ischemia significantly decreases left ventricular infarct size compared with animals receiving vehicle. Compared with sham animals, animals receiving vehicle have a significant increase in the infarct-to-area at risk

(AAR) ratio (70.7 ± 3.4 vs. $5.8 \pm 3.4\%$, P[1].

In Vivo: Inhibitors of MEK (AZD6244) and IKK (BAY 65-1942) are used at their IC_{50} concentrations, as determined by a 48 hour MTS assay, which achieve sufficient inhibition of kinase activity. MYL-R cells are treated for 24 hours with AZD6244 (5 μ M), BAY 65-1942 (10 μ M), or a combination of these inhibitors at the same concentrations. AZD6244 and BAY 65-1942 demonstrate synergistic inhibition of cell viability at the dose combination (5 μ M AZD6244+10 μ M BAY 65-1942), which correlates with IC_{75} ($CI=0.48 \pm 0.01$). Synergism is also indicated at the IC_{50} ($CI=0.56 \pm 0.09$) and IC_{90} ($CI=0.46 \pm 0.02$) dose combinations reported by the software (CI values are the mean of three independent experiments, \pm standard deviation). AZD6244 and BAY 65-1942 treatment induces 2- and 1.3-fold caspase 3/7 activation, respectively, compared to the DMSO-treated cells. Treatment with a combination of AZD6244 plus BAY 65-1942 leads to a 3.2-fold increase in caspase 3/7 activity^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!